Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
12 June 2020Website:
http://vaxcyte.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 21 Jun 2024 20:57:01 GMTDividend
Analysts recommendations
Institutional Ownership
PCVX Latest News
Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Vaxcyte (PCVX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Vaxcyte, Inc. is a clinical-stage vaccine company developing high-fidelity vaccines for bacterial diseases. The company's Q2 2023 earnings report shows significant growth in cash and investments, indicating a solid liquidity position. Positive Phase 2 data for Vaxcyte's VAX-24 vaccine and a promising pipeline make it a recommended speculative "Buy" for investors.
The average of price targets set by Wall Street analysts indicates a potential upside of 33.3% in Vaxcyte, Inc. (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vaxcyte is emerging as a leader in vaccine innovation, leveraging high-fidelity vaccines to combat bacterial diseases. The company's lead candidate, VAX-24, demonstrated robust immune responses and a favorable safety profile in its Phase 2 study in adults aged 65 and older.
Vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjugate vaccine candidate, VAX-24, in adults aged 65 and older.
When SVB Securities analyst David Risinger reiterated his bullish opinion on Vaxcyte, Inc. (NASDAQ: PCVX) last week, few investors noticed. The stock barely budged.
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, April 17, 2023, at 7:30 a.m. Eastern Time to discuss results from the Phase 2 study of VAX-24, the Company's lead, broad-spectrum 24-valent pneumococcal conjugate vaccine (PCV) candidate, in adults aged 65 and older and full six-month safety data from both adult Phase 2 studies.
What type of business is Vaxcyte?
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
What sector is Vaxcyte in?
Vaxcyte is in the Healthcare sector
What industry is Vaxcyte in?
Vaxcyte is in the Biotechnology industry
What country is Vaxcyte from?
Vaxcyte is headquartered in United States
When did Vaxcyte go public?
Vaxcyte initial public offering (IPO) was on 12 June 2020
What is Vaxcyte website?
https://vaxcyte.com
Is Vaxcyte in the S&P 500?
No, Vaxcyte is not included in the S&P 500 index
Is Vaxcyte in the NASDAQ 100?
No, Vaxcyte is not included in the NASDAQ 100 index
Is Vaxcyte in the Dow Jones?
No, Vaxcyte is not included in the Dow Jones index
When does Vaxcyte report earnings?
The next expected earnings date for Vaxcyte is 08 August 2024